Nakayama T, Morita S, Takashima T, Kamigaki, Yoshidome K, Ito T, Taguchi T, Sakamoto J, Noguchi S. Phase I Study of?S-1?in Combination with?Trastuzumab?for HER2-positive Metastatic
Breast Cancer.Anticancer Res 31(9):3035-9,2011 Aug.
Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y, Noguchi S. BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation.
Breast Cancer Res Treat 129(1):69-77,2011 Aug.
Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S. Prediction of pathologic complete response to sequential paclitaxel and
5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. Cancer. 2011 Aug 15;117(16):3682-90.
Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S. Development of 95-gene classifier as a powerful predictor of recurrences in node-negative
and ER-positive breast cancer patients. Breast Cancer Res Treat 128(3):633-41, 2011 Aug.
Miyake T, Shimazu K, Ohashi H, Taguchi T, Ueda S, Nakayama T, Kim SJ, Aozasa K, Tamaki Y, Noguchi S. Indication for sentinel lymph node biopsy for breast cancer when core biopsy shows ductal
carcinoma in situ. Am J Surg. 2011 Jul;202(1):59-65.
Nishimura R, Nakamura S, Oba K, Mitsuyama S, Hisamatsu K, Oriuchi N, Abe C, Kuwayama T, Taguchi T, Sakamoto J, and Noguchi S. Prospective study on the effect of toremifene in oatients with
adjuvant anastrozole failure in postmenopausal breast cancer. Ann. Cancer Res. Therap. 19(1):9-14, 2011.
Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S. High genomic grade index associated with poor prognosis for lymph node-negative and
estrogen receptor-positive breast cancers and with good response to chemotherapy. Cancer 117(3):472-9, 2011 Feb.